Literature DB >> 19174491

Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease.

N Ahmad Aziz1, Hanno Pijl, Marijke Frölich, A W Maurits van der Graaf, Ferdinand Roelfsema, Raymund A C Roos.   

Abstract

CONTEXT: Huntington's disease (HD) is a fatal hereditary neurodegenerative disorder characterized by motor, cognitive, and behavioral disturbances. Hypothalamic-pituitary-adrenal (HPA) axis dysfunction could contribute to a number of HD signs and symptoms; however, no data are available on cortisol diurnal variations and secretory dynamics in HD patients.
OBJECTIVE: The aim of the study was to perform a detailed analysis of HPA axis function in HD patients in relation to clinical signs and symptoms. DESIGN, SETTING, AND PARTICIPANTS: Twenty-four-hour cortisol secretion was studied in eight early-stage, medication-free HD patients and eight age-, sex-, and body mass index-matched controls in a clinical research laboratory. Cortisol levels were measured every 10 min. MAIN OUTCOME MEASURES: Multiparameter autodeconvolution and cosinor regression were applied to quantify basal, pulsatile, and total cortisol secretion rates as well as diurnal variations in cortisol levels.
RESULTS: Total cortisol secretion rate and the amplitude of the diurnal cortisol profile were both significantly higher in HD patients compared with controls (3490 +/- 320 vs. 2500 +/- 220 nmol/liter/24 h, P = 0.023; and 111 +/- 14 vs. 64 +/- 8 nmol/liter, P = 0.012, respectively). Cortisol concentrations in patients were particularly increased in the morning and early afternoon period. In HD patients, mean 24-h cortisol levels significantly correlated with total motor score, total functional capacity, as well as body mass index.
CONCLUSIONS: HPA axis hyperactivity is an early feature of HD and is likely to result from a disturbed central glucocorticoid feedback due to hypothalamic pathology. HPA axis dysfunction may contribute to some signs and symptoms in HD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19174491     DOI: 10.1210/jc.2008-2543

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  41 in total

1.  Increased irritability, anxiety, and immune reactivity in transgenic Huntington's disease monkeys.

Authors:  Jessica Raper; Steven Bosinger; Zachary Johnson; Gregory Tharp; Sean P Moran; Anthony W S Chan
Journal:  Brain Behav Immun       Date:  2016-07-07       Impact factor: 7.217

2.  Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.

Authors:  Thibault Renoir; Terence Y C Pang; Michelle S Zajac; Grace Chan; Xin Du; Leah Leang; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  'The clocks that time us'--circadian rhythms in neurodegenerative disorders.

Authors:  Aleksandar Videnovic; Alpar S Lazar; Roger A Barker; Sebastiaan Overeem
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

4.  Sleep in Huntington's disease: a systematic review and meta-analysis of polysomongraphic findings.

Authors:  Ye Zhang; Rong Ren; Linghui Yang; Junying Zhou; Yun Li; Jie Shi; Lin Lu; Larry D Sanford; Xiangdong Tang
Journal:  Sleep       Date:  2019-10-09       Impact factor: 5.849

Review 5.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

6.  Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.

Authors:  Charlotte Soneson; Magnus Fontes; Yongxia Zhou; Vladimir Denisov; Jane S Paulsen; Deniz Kirik; Asa Petersén
Journal:  Neurobiol Dis       Date:  2010-08-02       Impact factor: 5.996

Review 7.  Neurovascular glucocorticoid receptors and glucocorticoids: implications in health, neurological disorders and drug therapy.

Authors:  Sherice Williams; Chaitali Ghosh
Journal:  Drug Discov Today       Date:  2019-09-18       Impact factor: 7.851

8.  Delayed onset of the diurnal melatonin rise in patients with Huntington's disease.

Authors:  N Ahmad Aziz; Hanno Pijl; Marijke Frölich; Janny P Schröder-van der Elst; Chris van der Bent; Ferdinand Roelfsema; Raymund A C Roos
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

Review 9.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

10.  Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice.

Authors:  Thibault Renoir; Terence Y C Pang; Christina Mo; Grace Chan; Caroline Chevarin; Laurence Lanfumey; Anthony J Hannan
Journal:  J Physiol       Date:  2012-10-08       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.